MacKie R M, Andrew N, Lanyon W G, Connor J M
Department of Dermatology, University of Glasgow, Scotland, UK.
J Invest Dermatol. 1998 Aug;111(2):269-72. doi: 10.1046/j.1523-1747.1998.00267.x.
We report six of 16 U.K. melanoma families and two of 17 patients with multiple primary melanomas and a negative family history who have between them four different functionally damaging mutations of the CDKN2A (p16) gene: an Arg 24 Pro substitution in exon 1 in one family, a stop codon at codon 44 of exon 1 in one family, and a Met 53 Ile substitution in exon 2 in four families. One multiple primary melanoma patient also has the Met 53 Ile mutation and a second has a G-T substitution at the IVS2 + 1 splice donor site. Our data together with other recent publications from France and the U.S.A. indicate that screening melanoma kindreds with only two affected family members for CDKN2A mutations is justified.
我们报告了英国16个黑色素瘤家族中的6个家族,以及17例多发原发性黑色素瘤且家族史阴性的患者中的2例,他们共有4种不同的CDKN2A(p16)基因功能损伤性突变:一个家族外显子1中的Arg 24 Pro替换,一个家族外显子1中第44密码子处的终止密码子,以及4个家族外显子2中的Met 53 Ile替换。一名多发原发性黑色素瘤患者也有Met 53 Ile突变,另一名患者在IVS2 + 1剪接供体位点有G-T替换。我们的数据以及法国和美国最近的其他出版物表明,对只有两名受影响家庭成员的黑色素瘤家族进行CDKN2A突变筛查是合理的。